Notification
December 2015: AWMSG approvals
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales:
- Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX.
- Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane conductance regulator gene.
For both treatments, the approved patient access scheme should be used. Full details of restrictions are available from the AWMSG website.
Citation: The Pharmaceutical Journal URI: 20200428
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.
Visit rpharms.com
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.